EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors
In brief
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Key facts
- Study ID
- NCT07262619
- Run by
- Eikon Therapeutics
- People needed
- 160
- Starts
- 2026-01-20
- Expected to finish
- 2029-03-01
- Last updated by the study team
- 2026-04-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Health New Zealand — Wellington, New Zealand (enrolling)
- Calvary Mater Newcastle Hospital — Waratah, New South Wales, Australia (enrolling)
- Grampians Health — Ballarat, Victoria, Australia (enrolling)
- Chris O'Brien Lifehouse (Sydney Cancer Centre) — Camperdown, Victoria, Australia (enrolling)
- Peninsula and Southeast Oncology (PASO) Medical — Frankston, Victoria, Australia (enrolling)
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Memorial Sloan Kettering Cancer Center (MSKCC) — New York, New York, United States
- Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital — Frankston, Victoria, Australia
- GenesisCare North Shore (Oncology) — Saint Leonards, New South Wales, Australia
- Morristown Medical Center — Morristown, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.